Barclays Maintains Equal-Weight on Biomea Fusion, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Biomea Fusion (NASDAQ:BMEA) and raises the price target from $9 to $11.
October 30, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Peter Lawson has maintained an Equal-Weight rating on Biomea Fusion and increased the price target from $9 to $11, indicating a positive outlook.
The increase in the price target from $9 to $11 by Barclays suggests a positive outlook for Biomea Fusion, which could lead to a short-term increase in stock price. The Equal-Weight rating indicates a neutral stance, but the raised target price is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100